

**Clinical Trials Summary for out of hours
Important Reference**

Study Title	NuTide:701
Study Summary	A Phase I/II, open-label, dose-escalation and expansion study to assess the safety, pharmacokinetics and clinical activity of NUC 7738, a nucleotide analogue, in patients with advanced solid tumours and lymphoma
Principal Investigator	Professor Ruth Board Email: ruth.board@lthtr.nhs.uk Phone: 01772528251
Research Team responsible for the Study	Oncology Research Team/LCRF Team Sirjana Subedi Email: sirjana.subedi@lthtr.nhs.uk Ph:01772522136 Alan Brown Email: allan.brown@lthtr.nhs.uk Phone: 01772522031
Drug therapy	NUC-7738 will be administered Q1W (Cycle 1 Day 1, C1D8, C1D15, C2D1, C2D8, C2D15 etc) with concomitant Pembrolizumab Q3W (+/-1d) on the first day of each 21-day cycle.
ACTION to take if a patient calls this hotline/present at ED	Please treat as per clinical protocols and inform the clinical and research teams. Please liaise with the on-call Consultant or Registrar in the event of an emergency